AstraZeneca Results Presentation Deck
Lynparza
The globally-leading PARP¹ inhibitor
$m
600
500
400
300
200
100
Q1 2018
Lynparza
49% sales growth to $1.8bn
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
δ
Q3 2019
Lynnarza
04 2019
EMQ1 2020
Q2 2020
Q3 2020
Q4 2020
Product sales at actual exchange rates; changes at CER and for FY 2020, unless stated
otherwise. 1. Poly ADP ribose polymerase.
13
As
●
E
Approvals 78 (ovarian), 76 (breast), 55
(pancreatic) and 49 (prostate cancer)
AstraZeneca
US +40% (49% of total)
1st-line OC² growth supported
by new use in prostate cancer
Europe +51%
1st-line OC growth; emerging prostate
EMs +108%
OC launch; NRDL to expand use
2. Ovarian cancer.
EROW +32%
Japan: +27%; ~14% Q2 2020 price cut.
OC uptake continued
$
Q3 2017
Q4
2017
Q1 2018
Lynparza
collaboration revenue
Q2 2018
Q3
2018
Q4 2018
Q1 2019
22019
US-28859 4/19
Q3 2019
Q4 2019
301
2020
2020
Q3
Q2
2020
Q4 2020
Collaboration
revenue at actual
exchange rates.
Collaboration with Merck & Co., Inc., Kenilworth, NJ, US, known
side the US and Canada. $3.1bn revenue recorded; $4.6bn future potential.
$m
1,000
as MSD out-
800
600
- 200
400
0
$
THE
TRE
FOR PView entire presentation